Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients

Table 4 First stage time-dependent multivariate Cox model analysis of cytokine-induced killer cells immunotherapy at different frequencies and prognosis of the patients^1,2 (n = 154³)

Variables4	β	sβ	Wald-χ2	P-value	HR	95% CI
No. of CIK infusion	-0.620	0.200	9.592	0.002	0.54	0.36-0.80
Sex	0.294	0.298	0.969	0.325	1.34	0.75-2.41
Age	0.508	0.200	6.492	0.011	1.66	1.12-2.46
Tumor stages	0.739	0.202	13.377	0.0003	2.10	1.40-3.11
Relapse (yes or no)	3.363	0.719	21.848	< 0.0001	28.87	7.05-118.25

¹>All patients with survival time of longer than 36 mo (median value for total patients) were defined as the survivors;

²Pearson correlation test between Schoenfeld residual of cytokine-induced killer (CIK) cells immunotherapy frequency and survival time (r = 0.01, F = 0.01, P = 0.936);

³Missed patients;

⁴Variable value definition in the Cox model (frequency of CIK cells immunotherapy: 0 = 0 time, 1 = 1-10 times, 2 = 11-25 times, 3 = more than 25 times; Sex: 1 = man, 2 = woman), age (0 = ≤ 45 yr, 1 = about 60 yr, 2 = over 60 yr), tumor stage (0 = stage I, 1 = stage II, 2 = stage III, 3 = stage IV), relapse (1 = yes, 0 = no). HR: Hazard risk; 95% CI: 95% confidence interval.